|
Dr. Ecker is a co-founder of Isis Pharmaceuticals and currently serves as Vice President of Isis and Chief Scientific Officer of the Ibis division. He oversees all areas of the program including the TIGER biosensor and related biodefense initiatives, emerging infectious disease identification technology, drug discovery, patents, business development, strategic direction and the management of government and corporate partnerships.
Prior to founding Isis Pharmaceuticals, Dr. Ecker was Assistant Director, Department of Molecular Genetics at SmithKline and French Laboratories (SK&F). While at SmithKline and French Laboratories, he focused on applications of molecular biology to drug discovery. Dr. Ecker contributed to a number of SmithKline and French Laboratories therapeutic programs including cancer, arthritis/inflammation, antiviral and antifungal. He constructed and supervised the SK&F oligonucleotide synthesis facility.
Dr. Ecker has published in a number of fields, including biodefense technology development, chemistry, DNA synthesis, gene construction and expression, protein structure and function, enzymology and gene regulation. He has authored more than 100 scientific publications and issued US patents.
Dr. Ecker received his Ph.D. in chemistry and biochemistry from Utah State University, Logan, Utah, and was an American Cancer Society Fellow in chemistry at the University of California, Berkeley.
| 